NYSE:PEN

Penumbra (PEN) Stock Price, News & Analysis

$203.02
+0.30 (+0.15%)
(As of 04/22/2024 ET)
Today's Range
$200.86
$206.36
50-Day Range
$201.98
$273.27
52-Week Range
$180.93
$348.67
Volume
348,353 shs
Average Volume
327,753 shs
Market Capitalization
$7.86 billion
P/E Ratio
87.89
Dividend Yield
N/A
Price Target
$304.45

Penumbra MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
50.0% Upside
$304.45 Price Target
Short Interest
Healthy
4.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
1.05mentions of Penumbra in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.37 M Sold Last Quarter
Proj. Earnings Growth
39.65%
From $2.85 to $3.98 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.93 out of 5 stars

Medical Sector

15th out of 910 stocks

Surgical & Medical Instruments Industry

2nd out of 95 stocks

PEN stock logo

About Penumbra Stock (NYSE:PEN)

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN Stock Price History

PEN Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Critical Review: Penumbra (NYSE:PEN) vs. ProSomnus (NASDAQ:OSA)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Penumbra director sells $37,940 in company stock
Hey Ray - Become an eclipse expert
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/22/2024
Next Earnings (Confirmed)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Employees
4,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$304.45
High Stock Price Target
$376.00
Low Stock Price Target
$240.00
Potential Upside/Downside
+50.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$90.95 million
Pretax Margin
7.52%

Debt

Sales & Book Value

Annual Sales
$1.06 billion
Cash Flow
$2.83 per share
Book Value
$30.55 per share

Miscellaneous

Free Float
36,653,000
Market Cap
$7.86 billion
Optionable
Optionable
Beta
0.51
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives


PEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price target for 2024?

9 Wall Street research analysts have issued 12-month target prices for Penumbra's stock. Their PEN share price targets range from $240.00 to $376.00. On average, they predict the company's share price to reach $304.45 in the next twelve months. This suggests a possible upside of 50.0% from the stock's current price.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How have PEN shares performed in 2024?

Penumbra's stock was trading at $251.54 at the beginning of 2024. Since then, PEN stock has decreased by 19.3% and is now trading at $203.02.
View the best growth stocks for 2024 here
.

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our PEN earnings forecast
.

How can I listen to Penumbra's earnings call?

Penumbra will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) issued its quarterly earnings data on Thursday, February, 22nd. The company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.71 by $0.05. The business had revenue of $284.68 million for the quarter, compared to analyst estimates of $286.62 million. Penumbra had a trailing twelve-month return on equity of 7.49% and a net margin of 8.59%. The business's revenue was up 28.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.16 EPS.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.49%), Congress Asset Management Co. MA (0.07%), Norden Group LLC (0.05%), State of Michigan Retirement System (0.02%), Diversified Trust Co (0.02%) and Artemis Investment Management LLP (0.00%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends
.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PEN) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners